Immuron Reports Continued Sales Growth
Stocks in this Quantisnow insightHealth Care
Historical context for IMRN
Across the 3 sessions after earlier IMRN headlines, the stock closed higher 0 times and lower 3 times, with a median move of 10.9% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IMRN | SPY |
|---|---|---|---|
| Dec 3, 2025 | Immuron New U.S. Department of Defense Award & Clinical Trial Update | -10.9% | +0.3% |
| Nov 5, 2025 | Immuron IMM-529 IND approved by FDA | -12.7% | +0.3% |
| Oct 31, 2025 | Immuron Announces Clinical Trial Update | -5.9% | +0.3% |
Keep researching IMRN
Quantisnow market dataNASDAQ
IMRN
Immuron Limited
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2017
Get push alerts for IMRN
Full IMRN profile on Quantisnow Follow IMRN and get a push notification the moment its next story breaks.